Cargando…

IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Lewis, Eldrin F., Rhee, June-Wha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352260/ https://www.ncbi.nlm.nih.gov/pubmed/34396247 http://dx.doi.org/10.1016/j.jaccao.2020.08.003

Ejemplares similares

Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study
por: Correia, Luis C. L.
Publicado: (2016)

Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
por: Kim, Kyung‐Jin, et al.
Publicado: (2016)

Impact of Ezetimibe on New‐Onset Diabetes: A Substudy of IMPROVE‐IT
por: Shah, Nishant P., et al.
Publicado: (2023)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
por: Pradhan, Akshyaya, et al.
Publicado: (2020)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022)

Impact on urinary oxalate levels with use of ezetimibe
por: Trautman, Christopher L., et al.
Publicado: (2021)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Synthesis and Modeling of Ezetimibe Analogues
por: Salgado, Mateo M., et al.
Publicado: (2021)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT
por: Giugliano, Robert P., et al.
Publicado: (2020)

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
por: Dorff, Tanya, et al.
Publicado: (2023)

The Carcinogenic Azo- Compounds: Chemical Constitution and Carcinogenic Activity
por: Badger, G. M., et al.
Publicado: (1952)

A pilot study of the effect of ezetimibe for postprandial hyperlipidemia
por: Xue, E-Zhong, et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
por: Rea, Federico, et al.
Publicado: (2021)

Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014)

Ezetimibe therapy: mechanism of action and clinical update
por: Phan, Binh An P, et al.
Publicado: (2012)

Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability
por: Thadkala, Kiran, et al.
Publicado: (2014)

Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality
por: Patel, Akshar Y., et al.
Publicado: (2013)

Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial
por: Vattimo, Antonio Carlos Amedeo, et al.
Publicado: (2020)

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins
por: McQueen, R. Brett, et al.
Publicado: (2022)

Formulation and Evaluation of Linum usitatissimum Mucilage-Based Nanoparticles for Effective Delivery of Ezetimibe
por: Tulain, Ume Ruqia, et al.
Publicado: (2021)

The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
por: NODARI, SAVINA, et al.
Publicado: (2007)

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
por: Visseren, F. L. J.
Publicado: (2011)

Self-Micellizing Technology Improves the Properties of Ezetimibe and Increases Its Effect on Hyperlipidemic Rats
por: Torrado-Salmerón, Carlos, et al.
Publicado: (2019)

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2009)

Spectrophotometric and TLC-densitometric methods for the simultaneous determination of Ezetimibe and Atorvastatin calcium
por: Baghdady, Yehia Z., et al.
Publicado: (2013)

Comparative Study of Ezetimibe and Atorvastatin Alone and in Combination on Lipid Profile in Rats
por: Prasad, Anju, et al.
Publicado: (2013)

Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers
por: Park, Jungsin, et al.
Publicado: (2017)

Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients
por: Le, Ngoc‐Anh, et al.
Publicado: (2013)

Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice
por: Zhong, Yong, et al.
Publicado: (2012)

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition
por: Tie, Chunmiao, et al.
Publicado: (2015)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010)

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease
por: Guthrie, Robert
Publicado: (2010)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_09h8ivck0ou74uf48a1m282rlv